Immunomodulatory Effect of Rivaroxaban Nanoparticles Alone and in Combination with Sitagliptin on Diabetic Rat Model
This study underscores the promise of combining nanoparticle-based drug delivery with established therapies like sitagliptin to achieve superior immune modulation and inflammation control, presenting a potential therapeutic strategy for managing diabetes complications.
Authors
- Fawaz E. Alanazi (ORCID: https://orcid.org/0000-0002-8353-2066)
- Hashim M. Aljohani (ORCID: https://orcid.org/0000-0001-5333-6956)
- Noura H. Abd Ellah (ORCID: https://orcid.org/0000-0002-8326-4364)
- Heba A. Galal
- Helal F. Hetta (ORCID: https://orcid.org/0000-0001-8541-7304)
- Shereen Fawzy (ORCID: https://orcid.org/0000-0002-2810-8246)
- Ahmed Kamal Dyab (ORCID: https://orcid.org/0000-0002-4021-7904)
- Esraa A. Ahmed (ORCID: https://orcid.org/0000-0002-0412-0689)
- Marwa F. Ali (ORCID: https://orcid.org/0000-0001-6655-3570)
- Mohamed M. Elbadr
- Hassabelrasoul Elfadil (ORCID: https://orcid.org/0000-0002-7964-1294)
Institutions
- Taibah University (SA)
- University of Tabuk (SA)
- Assiut University (EG)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Diseases
- Published
- 2025-03-19
- DOI
- https://doi.org/10.3390/diseases13030087
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00